Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Cloverleaf Bio develops an RNA therapeutic platform for oncology.
Breye Therapeutics, a biopharmaceutical firm that provide cutting-edge oral treatments for the management of retinal vascular diseases.
Integrated Bio develops multimodal biological datasets and AI for drug discovery, focusing on therapeutics for age-related diseases.
Sensorium Therapeutics is a drug discovery platform that develops novel FDA-approved psychoactive medicines.
A biotechnology company developing RNA technologies to shape the future of gene therapy
INVENIO IMAGING is a privately held corporation
Deck Bio develops multi-target T cell engager immunotherapies for solid tumors.
March Biosciences is a clinical-stage cell therapy company that develops CAR-T cell strategies to address hematological cancers.
Beech Biotech is utilizing cutting-edge biology to develop innovative therapies for preeclampsia and other pregnancy-related issues.
Glycomine is an early-stage biotech working on replacement therapies for rare diseases.
TippingPoint Biosciences is developing therapeutics that target genome packaging states in diseases like cancer.
Umlaut.Bio is a spinout of the EMBL, is pursuing tRNA targets for treatment of cancer and immunological diseases.
D2B3is a pre-clinical biotechnology startup dedicated to creating innovative drug delivery technologies for the brain.
Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway.
AmbAgon Therapeutics is a developer of cancer molecule therapeutics.
Tune Therapeutics is an epigenetic programming platform for the treatment of disease.
Alessa Therapeutics develops localized treatments for solid organ disease.
Nuvig Therapeutics is a biotechnology company developing therapies to induce natural mechanisms to restore immune homeostasis.
Jupiter BioVentures is a creation engine company that focuses on de-risking early-stage projects.
ImmunOs Therapeutics is a clinical-stage biotechnology company.
Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation.
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
Enodia Therapeutics is a biotech company that provides transforming treatments for cancer, inflammation, and viral infection diseases.
Mission BioCapital has invested in 64 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Mission BioCapital's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Biopharma. The firm invests across 13 different industry categories.
Among tracked funding rounds, Tune Therapeutics received $175.0M in a Series B round. Mission BioCapital's total known invested capital is $3.2B.
Mission BioCapital's average investment size is $58.3M across its portfolio of 64 companies.
Recent Mission BioCapital portfolio additions include Cloverleaf Bio, Breye Therapeutics, Integrated Biosciences, Sensorium Therapeutics, Shape Therapeutics. These companies were founded in 2020 or later.